Steroid hormone receptor expression in ovarian cancer: Progesterone receptor B as prognostic marker for patient survival

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Lenhard, Miriam ^a   Tereza, Lennerová ^a   Heublein, Sabine ^a   Ditsch, Nina ^a   Himsl, Isabelle ^a   Mayr, Doris ^a   Friese, Klaus ^a   Jeschke, Udo ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Estrogen receptor alpha (ER ); Estrogen receptor beta (ER ); Ovarian cancer; Progesterone receptor A (PR A); Progesterone receptor B (PR B); Prognosis; Survival

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84869877511     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-553     Document Type: Article

References (39)

1. Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. Endocr Rev 2007, 28(4):440-461. 10.1210/er.2006-0036, 17463396.
2. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998, 90(23):1774-1786. 10.1093/jnci/90.23.1774, 9839517.
3. Chen FC, Oskay-Ozcelik G, Buhling KJ, Kopstein U, Mentze M, Lichtenegger W, Sehouli J. Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res 2009, 29(5):1575-1578.
4. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer-a short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007, 269(1-2):61-64.
5. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004, 191(3):733-740. 10.1016/j.ajog.2004.03.035, 15467532.
6. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307(5715):1625-1630. 10.1126/science.1106943, 15705806.
7. Sanden C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Martensson UE, Olde B, Leeb-Lundberg LM. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol Pharmacol 2011, 79(3):400-410. 10.1124/mol.110.069500, 21149639.
8. Savouret JF, Misrahi M, Milgrom E. Molecular action of progesterone. Int J Biochem 1990, 22(6):579-594. 10.1016/0020-711X(90)90033-Y, 2199252.
9. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990, 9(5):1603-1614. 551856, 2328727.
10. Bardin A, Moll F, Margueron R, Delfour C, Chu ML, Maudelonde T, Cavailles V, Pujol P. Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 2005, 146(2):760-768.
11. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990, 11(2):266-301. 10.1210/edrv-11-2-266, 2114281.
12. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005, 12(4):851-866. 10.1677/erc.1.01039, 16322326.
13. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004, 11(3):537-551. 10.1677/erc.1.00800, 2072930, 15369453.
14. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001, 142(6):2351-2360. 10.1210/en.142.6.2351, 11356682.
15. Simpson BJ, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JM, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF, et al. Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J Steroid Biochem Mol Biol 1998, 64(3-4):137-145.
16. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 1998, 58(9):1860-1865.
17. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43(16):2434-2444. 10.1016/j.ejca.2007.08.014, 17911007.
18. Kommoss F, Pfisterer J, Idris T, Giese E, Sauerbrei W, Schafer W, Thome M, Pfleiderer A. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol 1994, 16(3):203-210.
19. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007, 18(5):1051-1059.
20. Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies J, Sehouli J, Chekerov R, Dietel M, Denkert C. Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathology 2011, 59(5):918-927. 10.1111/j.1365-2559.2011.04028.x, 22092403.
21. Jeschke U, Walzel H, Mylonas I, Papadopoulos P, Shabani N, Kuhn C, Schulze S, Friese K, Karsten U, Anz D, et al. The human endometrium expresses the glycoprotein mucin-1 and shows positive correlation for Thomsen-Friedenreich epitope expression and galectin-1 binding. J Histochem Cytochem 2009, 57(9):871-881. 10.1369/jhc.2009.952085, 2728131, 19506091.
22. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8(3):138-140.
23. Asgari M, Morakabati A. Estrogen receptor beta expression in prostate adenocarcinoma. Diagn Pathol 2011, 6:61. 10.1186/1746-1596-6-61, 3151201, 21733187.
24. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005, 96(3):671-677. 10.1016/j.ygyno.2004.11.010, 15721410.
25. Burges A, Bruning A, Dannenmann C, Blankenstein T, Jeschke U, Shabani N, Friese K, Mylonas I. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2010, 281(3):511-517. 10.1007/s00404-009-1185-y, 19639330.
26. Geisler JP, Wiemann MC, Miller GA, Geisler HE. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Gynecol Oncol 1996, 60(3):424-427. 10.1006/gyno.1996.0067, 8774651.
27. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992, 47(3):317-322. 10.1016/0090-8258(92)90133-4, 1473744.
28. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990, 76(2):258-263.
29. Sevelda P, Denison U, Schemper M, Spona J, Vavra N, Salzer H. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol 1990, 97(8):706-712. 10.1111/j.1471-0528.1990.tb16243.x, 2400748.
30. Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 2001, 54(8):624-630. 10.1136/jcp.54.8.624, 1731503, 11477119.
31. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A, Sasano H. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 2000, 83(11):1488-1494. 10.1054/bjoc.2000.1463, 2363436, 11076658.
32. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000, 89(8):1783-1791. 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D, 11042574.
33. Anderl P, Fuith LC, Daxenbichler G, Marth C, Dapunt O. Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma. Gynecol Obstet Invest 1988, 25(2):135-140. 10.1159/000293760, 3371761.
34. Lenhard M, Lennerova T, Ditsch N, Kahlert S, Friese K, Mayr D, Jeschke U. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology 2011, 58(6):990-994. 10.1111/j.1365-2559.2011.03848.x, 21585434.
35. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1996, 62(1):4-6. 10.1006/gyno.1996.0181, 8690289.
36. Marth C, Sorheim N, Kaern J, Trope C. Tamoxifen in the treatment of recurrent 431 ovarian carcinoma. Int J Gynecol Cancer 1997, 7(4):256-261.
37. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2010, (3):CD001034.
38. Markman M, Webster K, Zanotti K, Rohl J, Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004, 93(2):390-393. 10.1016/j.ygyno.2004.01.035, 15099951.
39. Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012, 125(3):661-666. 10.1016/j.ygyno.2012.02.037, 22406638.